Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Weight loss varies by indication and dose, with approximately 15-21% reduction at higher doses in obesity trials and typically lower percentages in type 2 diabetes studies
Sci Rep 6(1):33655
The platform offers two active medications: compounded semaglutide (the same drug class as Ozempic and Wegovy) and compounded tirzepatide (comparable to Mounjaro and Zepbound)
Estimated reading time: 7 minutes Retatrutide has quickly become one of the most talked-about medications in obesity medicine, and it isnt even approved by the U.S
Seven additional Phase 3 readouts are expected this year, including the pivotal TRIUMPH-1 (general obesity) and TRIUMPH-2 (type 2 diabetes) trials
US$ 22.19
US$ 24.00
US$ 24.12
US$ 22.48
US$ 22.65
US$ 28.94
